Only patients with oncologic locally advanced or metastatic tumour (lung cancer research hub
41 indexed studies · 21 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)
This study looks at a new treatment called cabozantinib for liver cancer (hepatocellular carcinoma) in people who haven't responded to previous treatments. It aims to see how well it stops the cancer from growing and if it's safe to use. Patients will take tablets.
Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
This study is looking at new treatments for advanced liver cancer in people who haven't had treatment before. Researchers want to see how safe the new treatment is and if it can help slow down or shrink the cancer. It combines a new medicine called MK-1308A with an existing drug, Lenvatinib.
Spain · Italy · Poland - authorisedTherapeutic exploratory (Phase II)
F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival
This study looks at a special scan called F-18 PSMA-11 PET/CT to see how well it finds liver cancer (hepatocellular carcinoma). It aims to improve how doctors see and understand this type of cancer, and how patients respond to treatment.
Belgium - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)
This study is testing a new medicine, AZD9793, for adults with advanced solid cancers, especially liver cancer. It's looking at how safe the medicine is, how it moves through the body, and if it can help shrink tumours. It's an early-stage study, meaning it's one of the first times this medicine is being used in people.
Spain - active not recruitingPHASE3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study looks at a medicine called nivolumab for liver cancer. It's for people who've had surgery or other treatment to remove their cancer, but are at high risk of it coming back. We want to see if nivolumab can stop the cancer from returning.
United States · Argentina · Australia - recruiting
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
This study compares a quick, safe MRI scan to standard ultrasound for finding liver cancer early in people at high risk, like those with liver scarring (cirrhosis). The aim is to see if MRI can detect cancers that ultrasound might miss, offering a better screening method.
United Kingdom - active not recruitingPHASE1, PHASE2
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
This study is testing a new cell therapy called BOXR1030 for advanced cancers like liver, lung, and certain other solid tumours. It aims to see how safe it is and find the best dose.
United States · United Kingdom - recruiting
Prospective Cohort for Early Detection of Liver Cancer
This study aims to find better ways to detect liver cancer early in people with liver scarring (cirrhosis). Researchers will collect samples and information from 3000 volunteers to develop new, more effective tests.
United Kingdom - recruitingNA
Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
This study looks at a new test called Elecsys® GAAD to help doctors find liver cancer (hepatocellular carcinoma) earlier in people with liver scarring (cirrhosis). The aim is to see if this new test can improve current screening methods and help patients get treatment sooner.
United Kingdom - recruiting
The Detection of Small Early Liver Cancer With Natural History Follow up
The SELINA study aims to find better ways to detect early liver cancer in people with and without liver scarring (cirrhosis). We hope to improve survival by finding the cancer sooner. Participants will provide samples and some will have extra scans.
United Kingdom - active not recruitingNA
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
This study is looking at a new way to treat liver tumours using the HistoSonics System. It checks how safe and effective this treatment is for people with primary or metastatic liver cancer. Patients will be followed for up to five years.
Germany · Italy · Spain - recruitingPHASE1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.
United States · Belgium · Canada - active not recruitingNA
Blood Salvage in Orthotopic Liver Transplantation With HCC
This study looks into using a patient's own blood during liver transplant surgery for a type of liver cancer (HCC). We want to see if it's safe and helpful to give their blood back to them, or if it's better to use donated blood.
Canada - recruiting
The European NAFLD Registry
This study aims to understand fatty liver disease (NAFLD) better. Researchers collect information and samples from patients across Europe to find new ways to detect and monitor the disease, especially how it progresses from fatty liver to more serious conditions like fibrosis.
Belgium · Finland · France - recruitingPHASE1
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
This study is looking at a new way to treat advanced liver cancer that can't be removed with surgery. It combines two existing cancer drugs, ipilimumab and nivolumab. Doctors want to find the safest and most effective dose when ipilimumab is given directly into the liver and nivolumab is given into the bloodstream.
France - recruitingPHASE3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
This study compares two treatments for a type of liver cancer called hepatocellular carcinoma (HCC) in its intermediate stage. It looks at a combination of two drugs, atezolizumab and bevacizumab, against a standard treatment called TACE (Transarterial Chemoembolization), to see which works best and is safest.
Austria · France · Germany - active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
United States · Belgium · Brazil - recruitingPHASE1
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
This study is looking at a new drug (BAY 3547926) for advanced liver cancer. Researchers want to check its safety, how well it works, and find the best dose. The drug targets cancer cells with a special protein and uses a small amount of radiation to damage them.
United States · Belgium · Canada - recruitingNA
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
This study looks for new clues in blood samples to predict how well liver cancer patients will respond to a specific combination of immunotherapy drugs, tremelimumab and durvalumab. It aims to find out why some patients do better than others with this treatment.
France - active not recruitingPHASE1, PHASE2
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
This study is testing a new cancer medicine, BI-1910, alone and with another drug called pembrolizumab, for people with advanced solid tumours like lung cancer or liver cancer. It aims to find the right dose and check how safe and effective it is.
Denmark · Germany · Spain - recruiting
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
This study looks at how a specific marker called Glypican-3 (GPC-3) in the blood could help doctors tell if people with a type of liver cancer (hepatocellular carcinoma) will respond well to a new treatment. This new treatment combines two drugs, Atezolizumab and Bevacizumab.
France - recruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
United States · France · Italy - recruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
United States · Australia · Brazil - recruiting
Deep Liver Phenotyping and Immunology Study
This study aims to find better ways to spot liver cancers early, especially in people already at risk. Researchers are looking for clues in blood, urine, and liver samples that could show who might develop cancer, helping doctors treat it sooner.
United Kingdom - active not recruitingPHASE1
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
This study is looking into a new treatment for advanced liver cancer (hepatocellular carcinoma) that can't be removed by surgery. It combines a new drug, NP137, with two existing drugs, Atezolizumab and Bevacizumab, to see if it's safe and helps people live longer and respond better to treatment.
France - recruiting
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
This study looks at how liver diseases are linked to alcohol or unhealthy eating habits. Researchers want to understand why some people develop liver cancer, even in early stages, by studying health factors, body scans, and liver samples.
France - recruitingPHASE2
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
This study looks at adding a special bacteria (EXL01) to standard immunotherapy for advanced liver cancer (hepatocellular carcinoma). The goal is to help treatment work better for patients whose cancer hasn't responded well to initial immunotherapy.
France - recruitingPHASE3
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
This study compares two treatments for liver cancer: Transarterial Chemoembolization (TACE) alone versus TACE combined with Stereotactic Body Radiation Therapy (SBRT). It aims to see if adding SBRT, a focused radiation treatment, can better control the cancer and improve patient outcomes.
Canada - active not recruitingPHASE3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.
United States · Argentina · Australia - recruitingPHASE2
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
This study looks at a medicine called cabozantinib for patients who had liver cancer, received a liver transplant, and then their cancer came back. It aims to see how well cabozantinib works to control the cancer.
Canada - recruitingPHASE1
Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
This study is looking at a new way to treat liver cancer (hepatocellular carcinoma) by using targeted radiation before surgery. It aims to see if this combination treatment is safe and doesn't cause major delays or problems, with the goal of improving surgery results.
France - active not recruiting
naVIGation Invitations Liver surveillANce upTake
This study looks at new ways to help people attend vital liver scans for conditions like liver scarring or hepatitis B. It explores if special invitations and support from a Patient Navigator can improve attendance and lead to earlier cancer detection.
United Kingdom - active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
United States · Argentina · Australia - active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
United States · Australia · Austria - recruitingPHASE2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
This study looks at new ways to treat liver cancer before and after surgery. We're testing two drugs, pembrolizumab and lenvatinib, alone or together, to see if they can help stop the cancer from coming back after removal. It’s for people with liver cancer that can be surgically removed.
United Kingdom - active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Argentina · Austria · Belgium - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC pilot study
This study is looking at a new way to treat liver cancer (hepatocellular carcinoma) when previous immune treatments haven't worked. It combines two existing medicines, Avastin and Tecentriq, with something called Fecal Microbiota Transplant (FMT) to see if it helps patients and if it's safe.
Austria - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
United States · China · Hong Kong